CAH Treatment Drug Market Expected to Grow 8.1% Annually Through 2032

The global market for Congenital Adrenal Hyperplasia (CAH) treatment drugs is expected to grow at a Compound Annual Growth Rate (CAGR) of 8.1% from 2026 to 2032, according to a report by QY Research.

The market was valued at $639 million in 2025 and is projected to reach $1.095 billion by 2032, driven by increasing demand for CAH treatment and advancements in medical technology.

The top players in the market include Neurocrine Biosciences Inc., Amgen Inc., and Pfizer Inc., which are expected to continue their dominance due to their strong research capabilities and marketing efforts.